Gastric Signet Ring Cell Carcinoma: Tumor Microenvironment Reprogramming and Novel Therapeutic Targets With Emphasis on GRIN2D
Authors:
- Dipali RajuDRDipali Raju
- Swathi PrabhuSPSwathi Prabhu
- Anjal MariaAMAnjal Maria
- Shriya Narendra Shet ShirodkarSSShriya Narendra Shet Shirodkar
- Rama Rao DamerlaRDRama Rao Damerla
- Sanjiban ChakrabartySanjiban Chakrabarty
- Preethi S. ShettyPSPreethi S. Shetty
- Mahadev RaoMRMahadev Rao
- Naveena A. N. KumarNKNaveena A. N. Kumar
Open Access
- 18 November 2025
- journal article
- review article
- Published by Wiley in Clinical and Translational Science
- Vol. 18 (11) , e70424
Abstract
Gastric Signet Ring Cell Carcinoma (GSRCC) is an increasingly recognized subtype of gastric cancer, particularly prevalent in South Asian populations and regions within India. This carcinoma is distinguished by its abundant cytoplasmic mucinous cells and aggressive clinical behavior, often affecting younger individuals and leading to a poor prognosis due to its advanced‐stage presentation and resistance to standard treatments. A critical factor in its progression is the tumor's uniquely immunosuppressive and stromal‐rich microenvironment, characterized by dysfunctional immune infiltrates, activation of cancer‐associated fibroblasts, extracellular matrix remodeling, and complement cascade dysfunction. Recent research has highlighted the significance of key biomarkers, including MSMB, AGR2, CLDN18.2, and notably GRIN2D, which play roles in tumor angiogenesis, immune evasion, and metabolic reprogramming. The interaction of these elements contributes to therapeutic resistance and immune escape, thereby reducing the effectiveness of chemotherapy and checkpoint inhibitor immunotherapies. Innovative strategies that integrate stromal‐targeting agents, complement modulators, anti‐CLDN18.2 antibodies, and novel GRIN2D‐targeted therapies, along with precision molecular profiling, offer potential for enhancing patient outcomes. Tailored approaches that incorporate early detection and dynamic biomarker monitoring may ultimately transform GSRCC management toward personalized, evidence‐based therapies and prevention.Keywords
This publication has 71 references indexed in Scilit:
- Agr2 Mediates Paracrine Effects on Stromal Fibroblasts That Promote Invasion by Gastric Signet-Ring Carcinoma CellsCancer Research, 2015
- Matrix metalloproteinases and gastrointestinal cancers: Impacts of dietary antioxidantsWorld Journal of Biological Chemistry, 2014
- Pathohistological classification systems in gastric cancer: Diagnostic relevance and prognostic valueWorld Journal of Gastroenterology, 2014
- Targeting the Transforming Growth Factor-β Signaling in Cancer TherapyBiomolecules & Therapeutics, 2013
- Matrix metalloproteinases and their tissue inhibitors in gastric cancer as molecular markersJournal of Cancer Research and Therapeutics, 2013
- The complement system: History, pathways, cascade and inhibitorsEuropean Journal of Microbiology and Immunology, 2012
- Expression of Forkhead box P3 in tumour cells causes immunoregulatory function of signet ring cell carcinoma of the stomachBritish Journal of Cancer, 2012
- Epidemiological review of gastric cancer in IndiaIndian Journal of Medical and Paediatric Oncology, 2011
- From Single- to Multi-Target Drugs in Cancer Therapy: When Aspecificity Becomes an AdvantageCurrent Medicinal Chemistry, 2008
- The prognosis of patients with gastric cancer possessing sex hormone receptorsSurgery Today, 1992